Extension of Telemedicine to Treatment Management of Lentigo Maligna with Neoadjuvant Topical Imiquimod

Update item information
Identifier Extension-Treatment-Lentigo-Maligna-Neoadjuvent-Topical-Imiquimod_Lamb_NURS-4605_EBP_2020
Title Extension of Telemedicine to Treatment Management of Lentigo Maligna with Neoadjuvant Topical Imiquimod
Creator Andy Lamb, University of Utah BSN Student
Description Lentigo maligna is a superficial spreading subtype of melanoma that occurs on chronically sun exposed skin and does not exhibit invasion at the deep margin. Current standard of care is 3 months of neoadjuvant topical imiquimod treatment, followed by a 1-2 month recuperation period, and a definitive staged excision procedure. Topical imiquimod, when used effectively, can reduce tumor burden and required surgical margin, thus reducing cosmetic penalty. Treatment is monitored with monthly in-office follow ups and must be titrated to achieve optimal level of inflammation. Excess inflammation can cause pain, bleeding, oozing, flu-like symptoms, and risk for infection. Inadequate inflammation can compromise efficacy of treatment and lead to a more aggressive definitive surgery.
Subject Evidence-Based Nursing; Evidence-Based Practice; Education, Nursing; Telemedicine; Hutchinson's Melanotic Freckle; Imiquimod; Patient Satisfaction; Treatment Outcome; Research Design
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2020
Date Digital 2020
Language eng
ARK ark:/87278/s6799gg8
Relation is Part of Nursing 4605 Evidence Based Practice Posters
Format application/pdf
Rights Copyright © College of Nursing, University of Utah
Setname ehsl_nursebp
Date Created 2020-05-05
Date Modified 2020-05-18
ID 1547157
Reference URL https://collections.lib.utah.edu/ark:/87278/s6799gg8